I do not disagree... Wonder how much LEO CEO change played into "change in course"? ... seems to me LEO is more focused on dermatology than critical care
You do agree numerous studies show ATIII as promising for DIC and ATIII is used for DIC in Japan and some countries in Europe?
>> Hoping against hope LFB can get European ATryn sales moving.
The creation of a thousand forests is in one acorn.